The European Commission approved teclistamab plus daratumumab for relapsed multiple myeloma after a trial cut the risk of progression or death by more than 80%.
Revolution Medicines’ Rasonque (daraxonrasib) is the first targeted therapy to hit RAS — the mutation driving over 90% of pancreatic cancers — extending median survival to 13.2 months versus 6.7 on chemo.
In mice with glioblastoma, engineered nanoparticles lit up tumor clusters as small as a hair’s width during surgery, then destroyed microscopic leftover cells — and every treated animal survived.
While the industry chases GLP-1 agonists for weight loss, Amylyx went the other way — and its GLP-1 antagonist cut severe hypoglycemic events by 55% in a late-stage trial.
PIKTOR, an oral combination that hits the PI3K/AKT/mTOR pathway, won fast-track status alongside chemotherapy for endometrial cancer that has progressed despite prior treatment.
Hibsago (bepirovirsen) becomes the first therapy cleared anywhere aimed at functionally curing chronic hepatitis B — a milestone in a disease that infects hundreds of millions worldwide.